Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Exact Launches Real-World Trial Of Cologuard Colon Cancer Screening

Executive Summary

Exact Sciences Corp. and the Mayo Clinic are launching a 150,000-patient clinical trial examining the real-world effects of colorectal cancer screening with the Cologuard colon cancer test.

You may also be interested in...



USPSTF Recommendations For Colon Cancer Screening At Age 45 Could Give Cologuard A Boost

If the USPSTF recommendations are finalized, most insurers would need to reimburse Exact Sciences’ US FDA-approved at-home stool DNA test for colorectal cancer and encourage doctors to prescribe more at-home testing.

Despite Only Two Parallel Review Success Stories, CMS Touts Better Coordination

While only two devices have received approval and a national coverage determination through US FDA/CMS' parallel review program, a top CMS official says industry needs to look beyond just the numbers. Instead, she says the parallel review program is part of a sea-change that has allowed for better communication between CMS, FDA and sponsors.

US FDA Waits Until December To Enforce Unique Device Identifier Database For Low-Risk Devices

Agency won’t require manufacturers to submit class I devices to the database for an extra 75 days, and doesn't plan to enforce GUDID regulations against consumer health products. 

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT125804

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel